ACADIA Pharmaceuticals: Q3 Earnings Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data At Psych Congress 2021
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021,
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior
Where ACADIA Pharmaceuticals Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Guggenheim Upgrades ACADIA Pharmaceuticals to Buy, Announces $23 Price Target
Guggenheim analyst Yatin Suneja upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral to Buy and announces $23 price target.
Morgan Stanley Downgrades ACADIA Pharmaceuticals to Equal-Weight, Announces $20 Price Target
Morgan Stanley analyst Jeffrey Hung downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Overweight to Equal-Weight and announces $20 price target.